POS0277 EFFECT OF COLCHICINE THERAPY ON ATHEROSCLEROSIS-RELATED CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE
Authors: E. Cheremushkina, M. Eliseev, O. Sheliabina, A. Novikova, S. Glukhova
Journal: Annals of the Rheumatic Diseases (2022)

Background anti-inflammatory therapy supposed to influence the rate of cardiovascular events development in pts with calcium pyrophosphate deposition disease (CPPD). Objectives To assess the effect of colchicine, hydroxychloroquine, and methotrexate on cardiovascular outcomes (CVO) in CPPD pts. Methods The study included 305 pts with CPPD: 115 (37.70%) men, 190 (62.30%) women. The average follow-up period was 3.9±2.7 yrs. Among the factors influencing CVO were considered: gender, age, smoking, alcohol intake ≥20 standard doses/week, hypertension, history of cardiovascular disease (CVD): (ischemic heart disease (CHD), acute myocardial infarction myocardial infarction (AMI), acute cerebrovascular insufficiency (ACV), chronic heart failure (CHF) &gt;3 grade, NYHA), diabetes mellitus (DM), BMI &gt;25 kg/m 2 and &gt;30 kg/m 2 , cholesterol level &gt;5.1 mmol/l, GFR &lt;60 ml/min/1.73 m 2 , serim uric acid (sUA) &gt; 360 µmol/l, hypercalcemia (serum calcium&gt; 2.62 mmol/l), CRP&gt; 2 mg/l, hyperparathyroidism (parathyroid hormone&gt; 65 pg/ml), phenotypes of CPPD (asymptomatic, osteoarthritis with calcium pyrophosphate crystals (OA with CPP crystals), chronic arthritis, acute arthritis), taking colchicine, hydroxychloroquine and methotrexate, glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs). Information about mortality, regardless of cause, was noting down throughout the follow-up period. The causes of death were determined on the patient’s death certificate, and then classified according to the International Classification of Diseases of the 10-th Revision (ICD-10) All newly developed cases of non-fatal cardiovascular events were identified on the basis of medical documentation. The odds ratio (OR) with a 95% confidence interval of developing cardiovascular events was calculated. Statistica 12.0 package was used for statistical data processing. Results The mean age at inclusion was 58.9±12.5 yrs. 264 patients were available for follow-up. Any of the studied cardiovascular events were registered in 79 (29.9%) pts. During the follow-up period, 46 (17.4%) pts died; 35 of 46 (76.1%) pts died because of CVD; 11 (23.9%) pts died due to other causes. Non-fatal cardiovascular events were registered in 44 (16.7%) pts. The risk of cardiovascular events was higher for ps aged &gt;65 years (OR 5.97, 95% CI 3.33-10.71), serum cholesterol level ≥5.1 mmol/l (OR 1.95, 95% CI 1.04-3.65]), GFR &lt;60 ml/min/1.73 m 2 (OR 2.78, 95% CI 1.32-5.56]), history of CVD (OR 2.32, 95% CI 1.22-4.44) Colchicine therapy was associated with the lower risk of cardiovascular events (OR 0.20, 95% CI 0.11-0.39]). Therapy with methorexate and hydroxychloroquine did not exert an influence on opportunity of CVO. Conclusion Adverse CVD outcomes in CPPD pts are associated with age, hypercholesterolemia, CKD, and a history of CVD. The intake of colchicine, but not methotrexate and hydroxychloroquine, by patients with CPPD is associated with decline of risk of cardiovascular events. References [1]Bashir M, Sherman KA, Solomon DH, et al. Cardiovascular disease risk in calcium pyrophosphate deposition disease: A nationwide study of veterans. Arthritis Care Res (Hoboken). 2021 Sep 14. doi: 10.1002/acr.24783. Disclosure of Interests Elena Cheremushkina: None declared, Maxim Eliseev Speakers bureau: Berlin Chemie Menarini Group, Sobi, EGIS, CSC, MosFarma, Alium Group, Olga Sheliabina Speakers bureau: Berlin Chemie Menarini Group, Aleksandra Novikova: None declared, Svetlana Glukhova: None declared